Cell of Origin and MYC Rearrangements and Outcomes in Patients
Research type
Research Study
Full title
Impact of Immunohistochemistry-defined Cell of Origin and MYC Rearrangements on Outcomes in Patients with PET-defined Limited Stage Diffuse Large B-cell Lymphoma Treated with R-CHOP ± Radiotherapy: an International Multi-center Retrospective Study
IRAS ID
219375
Contact name
Mark Bishton
Contact email
Sponsor organisation
R&I, Nottingham University Hospitals NHS Trust
Duration of Study in the UK
0 years, 1 months, 31 days
Research summary
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in adults. About 30-40% of have early stage I/II disease which generally has a very good cure rate. We know with more advanced stage disease that, although uncommon, if the cancer expresses MYC and BCL2 proteins or chromosome abnormalities usually have poor outcomes in advanced disease. A lot of Doctors will therefore use very strong chemotherapy regimens to try and improve outcomes among such patients. We don’t know if these abnormalities are as important in patients with early stage disease and so we want to look at samples of previously treated patients with early stage disease and find out if MYC and BCL2 proteins or chromosome abnormalities in these patients alter the good outcomes expected. As these changes are rare we need large international databases to find enough patients to find the answer.
REC name
East Midlands - Derby Research Ethics Committee
REC reference
17/EM/0053
Date of REC Opinion
23 Feb 2017
REC opinion
Further Information Favourable Opinion